- Home
- MPW vs NAMS Comparison
MPW vs NAMS Comparison
Compare MPW & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPW
- NAMS
- Stock Information
- Founded
- MPW 2003
- NAMS 2019
- Country
- MPW United States
- NAMS Netherlands
- Employees
- MPW N/A
- NAMS N/A
- Industry
- MPW Real Estate Investment Trusts
- NAMS Biotechnology: Pharmaceutical Preparations
- Sector
- MPW Real Estate
- NAMS Health Care
- Exchange
- MPW Nasdaq
- NAMS Nasdaq
- Market Cap
- MPW 2.9B
- NAMS 3.1B
- IPO Year
- MPW 2005
- NAMS N/A
- Fundamental
- Price
- MPW $5.81
- NAMS $41.50
- Analyst Decision
- MPW Hold
- NAMS Strong Buy
- Analyst Count
- MPW 6
- NAMS 10
- Target Price
- MPW $5.42
- NAMS $44.80
- AVG Volume (30 Days)
- MPW 9.1M
- NAMS 1.0M
- Earning Date
- MPW 10-30-2025
- NAMS 11-05-2025
- Dividend Yield
- MPW 5.55%
- NAMS N/A
- EPS Growth
- MPW N/A
- NAMS N/A
- EPS
- MPW N/A
- NAMS N/A
- Revenue
- MPW $1,009,160,000.00
- NAMS $35,243,000.00
- Revenue This Year
- MPW N/A
- NAMS N/A
- Revenue Next Year
- MPW $9.68
- NAMS N/A
- P/E Ratio
- MPW N/A
- NAMS N/A
- Revenue Growth
- MPW 52.52
- NAMS 4.91
- 52 Week Low
- MPW $3.51
- NAMS $14.06
- 52 Week High
- MPW $6.34
- NAMS $42.00
- Technical
- Relative Strength Index (RSI)
- MPW 72.49
- NAMS 65.27
- Support Level
- MPW $4.98
- NAMS $36.59
- Resistance Level
- MPW $5.24
- NAMS $40.88
- Average True Range (ATR)
- MPW 0.17
- NAMS 2.56
- MACD
- MPW 0.08
- NAMS 0.06
- Stochastic Oscillator
- MPW 98.94
- NAMS 94.13
About MPW Medical Properties Trust Inc. common stock
Medical Properties Trust Inc acquires and develops net-leased healthcare facilities. Its investments in healthcare real estate, other loans, and any investments in tenants are considered a single reportable segment. The group's geographic areas are the United States, the United Kingdom, and All other countries.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.